Green Success Pivots to AI Infrastructure with BH Labs Rebrand

Green Success, the European medical cannabis brand-access platform, announced it is rebranding as BH Labs, positioning itself as an AI-driven operational infrastructure layer for regulated healthcare markets rather than a supply-and-distribution intermediary.

The rebrand formalizes a strategic shift that founder and chief executive Yuval Soiref has been signaling publicly in recent months. Europe’s first commercial phase in medical cannabis was largely a logistics problem: securing EU-GMP certification, building supply chains to pharmacies, and assembling brand portfolios with sufficient market recognition to navigate the regulatory requirements of Germany and the UK. BH Labs is a bet that the next competitive advantage in the market lies in the infrastructure connecting all those pieces.

From Brand Access to Operating System

Green Success built its European footprint by doing something specific and difficult: moving North American cannabis brands into the tightly regulated medical markets of Germany and the UK. The company says it holds EU-GMP certification through production operations in North Macedonia, and its brand portfolio includes Tyson 2.0, Seed Junky, Cali X, and Packs — California-origin names with established market recognition.

That work gave the company hands-on exposure to the friction points across the full medical supply chain. Soiref says what he observed operating across Germany, the UK, and international supply corridors was a market organized around isolated, non-communicating parts.

“Cultivators focused only on cultivation. Telemedicine companies focused only on patients. Distributors focused only on logistics,” Soiref said. “Very few companies were actually building the intelligent infrastructure connecting everything together.”

BH Labs is structured as the response to that gap. The company describes a consolidated platform connecting supply infrastructure, telemedicine, patient acquisition, marketplace technology, distribution, and analytics — with AI positioned as the coordination layer across the system. Soiref frames AI inside BH Labs not as a customer-facing tool but as operational intelligence embedded in the organization’s workflows: sales tracking, supply synchronization, performance marketing optimization, and decision-making across the platform.

The MedReleaf Investment and European Thesis

Soiref traces his entry into cannabis to his family’s early investment in MedReleaf Corp., one of Canada’s first institutional-scale licensed producers. Aurora Cannabis (ACB ) acquired MedReleaf in July 2018 for approximately C$3.2 billion — at the time, the largest cannabis M&A transaction in Canada.

Watching a regulated market move through cultivation-first, then brand differentiation, public markets, and eventual large-scale exit gave Soiref a framework for reading European cannabis development. The infrastructure investments that create durable value, his reasoning goes, come ahead of the consolidation phase rather than during it. Green Success was built on that thesis; BH Labs is its articulation as an integrated technology platform.

Soiref’s technology orientation has roots in his pre-cannabis career. He has described years of work in technology and cybersecurity before entering the cannabis industry, and the company characterizes the AI integration as an extension of how the organization already thought about operational systems rather than a strategic retrofit.

Launches and What to Watch

The company’s next phase centers on two patient-access platforms: ZAZAMED Germany, which the company says is entering the launch stage, and Better Health Medical in the UK, alongside ZAZAMED UK. BH Labs describes these not as standalone clinics but as integrated ecosystems designed to connect telemedicine, patient onboarding, product access, pharmacy fulfillment, and ongoing patient engagement within a single platform.

These launches will provide the first real commercial test of BH Labs’ infrastructure thesis. The company is privately held — registered in England as BH Labs Limited — and has not publicly disclosed financial metrics or independent technology audits. The platform’s claims about AI-driven operational efficiency and integrated patient acquisition will ultimately be measured against commercial outcomes: patient volumes, retention economics, and whether the integrated model actually reduces friction relative to the fragmented operators it is designed to displace.

Broader market dynamics set a relevant backdrop. Germany’s medical cannabis sector is actively consolidating, with multinational operators competing to control multiple points of the value chain. UK cannabis import volumes continue to climb as patient demand outpaces domestic supply capacity. Both markets are moving toward infrastructure-level competition in ways that favor operators with integrated platforms over single-layer specialists.

BH Labs is placing an early, structured bet on that direction. Whether the technology and operational stack it is assembling can deliver on the promise of an integrated platform is the question that this year’s launch activity will begin to answer.